Skip to main content
. Author manuscript; available in PMC: 2013 Aug 28.
Published in final edited form as: Pain. 2010 Feb 19;149(1):135–142. doi: 10.1016/j.pain.2010.01.024

Fig. 2.

Fig. 2

Complement-dependent cytotoxicity in the presence of varying concentrations of ch14.18 or hu14.18K322A was determined in a 2 h Europium-TDA release assay. In the presence of 0.5% human serum complement ch14.18 elicits a much stronger CDC than does hu14.18K322A.